SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

TREM2 in Parkinson's Disease — Cross-Disease Therapeutic Opportunity

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-trem2-parkinsons-disease
Related Entities
mechanisms-trem2-parkinsons-disease
Metadata
slugmechanisms-trem2-parkinsons-disease
entity_typemechanism
kg_node_idNone
Linked Artifacts (402)
mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia90%
mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination80%
mentions🧪TREM2-mediated microglial tau clearance enhancement80%
mentions🔬Immune atlas neuroinflammation analysis in neurodegeneration75%
mentions🔬Neuroinflammation and microglial priming in early Alzheimer&75%
mentions🔬Neuroinflammation and microglial priming in early AD — Analy75%
mentions🔬Does SYK activation provide neuroprotection or exacerbate ne75%
mentions🔬What are the optimal timing windows for TREM2 agonism vs ant75%
mentions🔬Analysis question not specified75%
mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia70%
mentions🧫s:** - GPR32 knockout in microglia should worsen neuroinflam70%
mentions🧫Proposed experiment from debate on Synaptic pruning by micro70%
mentions🧫Proposed experiment from debate on Synaptic pruning by micro70%
mentions🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional70%
mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti70%
mentions🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy70%
mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
mentions🧫Experiment: Autoimmune Hypothesis Testing in AD70%
mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%
mentions🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi70%
mentions🧫DLB Cognitive Fluctuation Mechanism Experiment70%
mentions🧫Genetic Risk Modifiers in DLB Phenotype70%
mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%
mentions🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%
mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation70%
mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr70%
mentions🧫Microglial Contributions to Huntington's Disease Pathog70%
mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress70%
mentions🧫Prodromal Parkinson's Disease Biomarker Development — E70%
mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%
mentions🧫PSP and CBS Biomarker Validation Study70%
mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo70%
mentions🧫Experiment Validation: In vitro ThT Assay70%
mentions🧫Tau ASO Therapy70%
mentions🧫Microglial TREM2 Agonist In Vivo Efficacy70%
mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim70%
mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧫TREM2 KO amyloid pathology study70%
mentions🧪TREM2-mediated microglial tau clearance enhancement70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%
related🧫Microglial TREM2 Agonist In Vivo Efficacy70%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim70%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%
related🧪APOE-TREM2 Interaction Modulation70%
mentions🧪Microbial Inflammasome Priming Prevention69%
mentions🧪Purinergic P2Y12 Inverse Agonist Therapy69%
mentions🧪Microglial Purinergic Reprogramming68%
mentions🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri68%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy67%
related🔬Immune atlas neuroinflammation analysis in neurodegeneration67%
related🔬Neuroinflammation and microglial priming in early Alzheimer&67%
related🔬Neuroinflammation and microglial priming in early AD — Analy67%
related🔬Does SYK activation provide neuroprotection or exacerbate ne67%
related🔬What are the optimal timing windows for TREM2 agonism vs ant67%
related🔬Analysis question not specified67%
mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones67%
mentions🧪Smartphone-Detected Motor Variability Correction66%
mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination65%
mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer65%
mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides65%
mentions🧪Optogenetic Microglial Deactivation via Engineered Inhibitor65%
mentions🧪Microbial Metabolite-Mediated α-Synuclein Disaggregation65%
related🧪Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro65%
related🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition65%
related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi65%
related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists65%
related🧪Orexin-Microglia Modulation Therapy65%
related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding65%
related🧪TREM2-Mediated Selective Aggregate Clearance Pathway65%
related🧪TREM2-mediated microglial tau clearance enhancement65%
related🧪TREM2-Dependent Microglial Senescence Transition65%
related🧪Low Complexity Domain Cross-Linking Inhibition65%
related🧪Transglutaminase-2 Cross-Linking Inhibition Strategy65%
mentions🧪Enteric Nervous System Prion-Like Propagation Blockade64%
mentions🧪Competitive APOE4 Domain Stabilization Peptides64%
mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction63%
related🧫s:** - GPR32 knockout in microglia should worsen neuroinflam63%
related🧫Proposed experiment from debate on Synaptic pruning by micro63%
related🧫Proposed experiment from debate on Synaptic pruning by micro63%
related🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional63%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti63%
related🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy63%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%
related🧫Experiment: Autoimmune Hypothesis Testing in AD63%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%
related🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi63%
related🧫DLB Cognitive Fluctuation Mechanism Experiment63%
related🧫Genetic Risk Modifiers in DLB Phenotype63%
related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%
related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud63%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation63%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr63%
related🧫Microglial Contributions to Huntington's Disease Pathog63%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress63%
related🧫Progranulin Replacement Therapy for FTD — Vector Development63%
related🧫PSP and CBS Biomarker Validation Study63%
related🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo63%
related🧫Experiment Validation: In vitro ThT Assay63%
related🧫Tau ASO Therapy63%
related🧫Microglial TREM2 Agonist In Vivo Efficacy63%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim63%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧫TREM2 KO amyloid pathology study63%
related🧪TREM2-mediated microglial tau clearance enhancement63%
related🧪Microbial Inflammasome Priming Prevention62%
related🧪Purinergic P2Y12 Inverse Agonist Therapy62%
related🧪Microglial Purinergic Reprogramming61%
related🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri61%
related🧪Targeted APOE4-to-APOE3 Base Editing Therapy60%
related🧪APOE4 Allosteric Rescue via Small Molecule Chaperones60%
mentions🧪APOE-TREM2 Interaction Modulation60%
mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway60%
mentions🧪TREM2-Dependent Microglial Senescence Transition60%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR60%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR60%
mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%
related🧫AAV-LRRK2 IND-Enabling Study Design60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%
related🧫Alpha-Synuclein Seed Amplification Assay Validation60%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%
related🧫Antiviral Therapy Trial for Parkinson's Disease60%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%
related🧫Combination Therapy Sequencing in Parkinson's Disease60%
related🧫CRISPR Gene Correction Approaches for CBS/PSP60%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%
related🧫Ferroptosis Validation in Parkinson's Disease60%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%
related🧫Cytochrome Therapeutics60%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%
related🧫Macroautophagy Dysfunction in PD - Experiment Design60%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%
related🧫Validation: Membrane-Nucleation in iPSC Neurons60%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%
related🧫MLCS Quantification in Parkinson's Disease60%
related🧫Experiment: Multi-Ethnic PD GWAS60%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%
related🧫Parkinson's Disease Subtype Classification — Precision 60%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%
related🧫Prodromal Parkinson's Disease Biomarker Development — E60%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%
related🧪Smartphone-Detected Motor Variability Correction59%
related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination59%
related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer59%
related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides59%
related🧪Optogenetic Microglial Deactivation via Engineered Inhibitor58%
related🧪Microbial Metabolite-Mediated α-Synuclein Disaggregation58%
related🧪Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro58%
related🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition58%
related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi58%
related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists58%
related🧪Orexin-Microglia Modulation Therapy58%
related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding58%
related🧪Transglutaminase-2 Cross-Linking Inhibition Strategy58%
related🧪Enteric Nervous System Prion-Like Propagation Blockade57%
related🧪Competitive APOE4 Domain Stabilization Peptides57%
related🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction56%
related🧪APOE-TREM2 Interaction Modulation54%
related🧪TREM2-Mediated Selective Aggregate Clearance Pathway54%
related🧪TREM2-Dependent Microglial Senescence Transition54%
related🔬The disease-associated microglia (DAM) phenotype involves TR54%
related🔬The disease-associated microglia (DAM) phenotype involves TR54%
related🔬Comprehensive analysis of immune cell subtypes in neurodegen54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%
related🧫AAV-LRRK2 IND-Enabling Study Design54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%
related🧫Alpha-Synuclein Seed Amplification Assay Validation54%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%
related🧫Antiviral Therapy Trial for Parkinson's Disease54%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%
related🧫Combination Therapy Sequencing in Parkinson's Disease54%
related🧫CRISPR Gene Correction Approaches for CBS/PSP54%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%
related🧫Ferroptosis Validation in Parkinson's Disease54%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%
related🧫Cytochrome Therapeutics54%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%
related🧫Macroautophagy Dysfunction in PD - Experiment Design54%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%
related🧫Validation: Membrane-Nucleation in iPSC Neurons54%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%
related🧫MLCS Quantification in Parkinson's Disease54%
related🧫Experiment: Multi-Ethnic PD GWAS54%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%
related🧫Parkinson's Disease Subtype Classification — Precision 54%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%
related🧫Prodromal Parkinson's Disease Biomarker Development — E54%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%
mentions🧪APOE Isoform Conversion Therapy50%
mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%
mentions🧪APOE Isoform Expression Across Glial Subtypes50%
mentions🧪Low Complexity Domain Cross-Linking Inhibition50%
mentions🧪Cross-Seeding Prevention Strategy50%
mentions🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m50%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying digital biomarkers and ai50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬What are the mechanisms underlying selective vulnerability o50%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
related🔬What are the mechanisms underlying astrocyte reactivity subt50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying microglia-astrocyte cross50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying digital biomarkers and ai50%
related🔬What are the mechanisms underlying senolytic therapy for age50%
related🔬What are the mechanisms underlying neuroinflammation resolut50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬What are the mechanisms underlying protein aggregation cross50%
related🔬What are the mechanisms underlying mechanistic role of apoe 50%
related🔬What are the mechanisms underlying sleep disruption as cause50%
related🔬What are the mechanisms underlying rna binding protein dysre50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬What are the mechanisms underlying mitochondrial transfer be50%
related🔬What are the mechanisms underlying epigenetic clocks and bio50%
related🔬What are the mechanisms underlying perivascular spaces and g50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What gene expression changes in the aging mouse brain predic50%
related🔬What cell types are most vulnerable in Alzheimers Disease ba50%
related🔬What cell types are most vulnerable in Alzheimer's Dise50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬What are the mechanisms by which tau pathology spreads throu50%
related🔬How does metabolic reprogramming (glucose metabolism shifts,50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬What are the most promising therapeutic strategies for targe50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%
related🔬TDP-43 undergoes liquid-liquid phase separation that becomes50%
related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%
related🔬Multiple NDDs converge on autophagy-lysosome dysfunction. Ar50%
related🧪Membrane Cholesterol Gradient Modulators50%
see_also📖TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th50%
see_also📖sTREM2 (Soluble TREM2) - Microglial Biomarker45%
see_also📖sTREM2 (Soluble TREM2) - Biomarker45%
see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh45%
see_also📖al002-trem2-agonist-alzheimers45%
see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer45%
see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 45%
see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 45%
see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC45%
see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St45%
see_also📖Master Screening Study to Determine Individuals With Potenti45%
see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A45%
see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime45%
see_also📖TREM2 Gene45%
see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease45%
see_also📖Endolysosomal Pathway in Alzheimer's Disease45%
see_also📖Geniposide for Alzheimer's disease - immune biomarker t45%
see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa45%
see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease45%
see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ45%
see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease45%
see_also📖Sporadic Alzheimer's Disease Pathway45%
see_also📖Synaptic Loss in Alzheimer's Disease Pathway45%
see_also📖TREM2 in Amyotrophic Lateral Sclerosis45%
see_also📖TREM2 in Frontotemporal Dementia45%
see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's45%
mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi44%
mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau44%
mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and44%
mentions🧫Experiment: Multi-Ethnic PD GWAS44%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What gene expression changes in the aging mouse brain predic40%
mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%
mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%
mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%
mentions🔬What are the mechanisms underlying selective vulnerability o40%
mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp40%
mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%
mentions🔬What are the mechanisms underlying astrocyte reactivity subt40%
mentions🔬What are the mechanisms underlying blood-brain barrier trans40%
mentions🔬What are the mechanisms underlying microglia-astrocyte cross40%
mentions🔬What are the mechanisms underlying apoe4 structural biology 40%
mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%
mentions🔬What are the mechanisms underlying digital biomarkers and ai40%
mentions🔬What are the mechanisms underlying senolytic therapy for age40%
mentions🔬What are the mechanisms underlying neuroinflammation resolut40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬What are the mechanisms underlying mitochondrial transfer be40%
mentions🔬What are the mechanisms underlying protein aggregation cross40%
mentions🔬What are the mechanisms underlying mechanistic role of apoe 40%
mentions🔬What are the mechanisms underlying sleep disruption as cause40%
mentions🔬What are the mechanisms underlying rna binding protein dysre40%
mentions🔬What are the mechanisms underlying synaptic pruning by micro40%
mentions🔬What are the mechanisms underlying mitochondrial transfer be40%
mentions🔬What are the mechanisms underlying epigenetic clocks and bio40%
mentions🔬What are the mechanisms underlying perivascular spaces and g40%
mentions🔬What are the mechanisms by which tau pathology spreads throu40%
mentions🔬Analyze circuit-level changes in neurodegeneration using All40%
mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%
mentions🔬What are the most promising therapeutic strategies for targe40%
mentions🔬TDP-43 undergoes liquid-liquid phase separation that becomes40%
mentions🔬Multiple NDDs converge on autophagy-lysosome dysfunction. Ar40%
related🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m40%
related🧪Low Complexity Domain Cross-Linking Inhibition40%
related🧪Cross-Seeding Prevention Strategy40%
related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination35%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia35%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub